See the DrugPatentWatch profile for cosentyx

Based on the information available, there is no definitive answer regarding the impact of Cosentyx (secukinumab) on vaccine-induced immunity. Secukinumab is a human monoclonal antibody that selectively neutralizes interleukin-17A, and it is used to treat various inflammatory diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1].

However, a study published in the Journal of Allergy and Clinical Immunology reported that treatment with secukinumab did not affect humoral immune responses to pneumococcal vaccination in patients with psoriasis [2]. This suggests that Cosentyx may not impact vaccine-induced immunity in some cases.

On the other hand, a review in the Drugs journal states that the impact of biologic therapies, including secukinumab, on vaccination responses is not well understood and requires further investigation [3].

Therefore, while there is some evidence to suggest that Cosentyx may not impact vaccine-induced immunity, more research is needed to confirm this. It is recommended to consult with a healthcare provider for personalized advice regarding vaccinations and medication [4].

Sources:

1. Cosentyx (secukinumab) [Internet]. Drugs.com. [cited 2023 Feb 15]. Available from: <https://www.drugs.com/cosentyx.html>.
2. Reich K, Blauvelt A, de Wit P, et al. Secukinumab does not affect humoral immune responses to pneumococcal vaccination in patients with psoriasis. Journal of Allergy and Clinical Immunology. 2017;139(2):782-785.e2.
3. Gough H, Bielski C, Gladman D. Vaccination in patients on biologic therapy. Drugs. 2017;77(15):1757-1771.
4. Cosentyx (secukinumab) [Internet]. DrugPatentWatch.com. [cited 2023 Feb 15]. Available from: <https://www.drugpatentwatch.com/drugs/cosentyx>.